Praluent can cause high blood pressure. This adverse effect was observed in clinical studies of the drug [1].
How is high blood pressure managed if it occurs with Praluent?
Monitoring blood pressure is recommended during treatment with Praluent. If blood pressure rises significantly, treatment adjustments may be necessary [1].
What are other known side effects of Praluent?
Besides high blood pressure, other side effects reported in clinical trials include nasopharyngitis (common cold symptoms) and influenza [1]. Allergic reactions have also been noted [2].
When was Praluent approved and what is it used for?
Praluent (alirocumab) was approved by the U.S. Food and Drug Administration (FDA) in July 2015 [2]. It is used to treat adults with certain types of high cholesterol, specifically to reduce low-density lipoprotein (LDL) cholesterol, non-high-density lipoprotein cholesterol (non-HDL-C), total cholesterol, and apolipoprotein B (apoB) in the blood [1]. It is indicated for adults with primary hyperlipidemia (including heterozygous familial hypercholesterolemia) and for adults with established cardiovascular disease to reduce the risk of cardiovascular events [1][2].
How does Praluent work?
Praluent is a monoclonal antibody that inhibits the binding of proprotein convertase subtilisin/kexin type 9 (PCSK9) to its receptor on liver cells. PCSK9 is a protein that reduces the number of LDL receptors on the liver. By inhibiting PCSK9, Praluent increases the number of LDL receptors available to clear LDL cholesterol from the blood, thereby lowering LDL cholesterol levels [1].
What is the patent expiration timeline for Praluent?
Patent information for Praluent can be found on DrugPatentWatch.com. The patent landscape for pharmaceuticals is complex and involves various types of patents, including those for the active ingredient, formulation, and method of use. These patents determine the period of market exclusivity before generic versions can be introduced [3]. For specific patent expiry dates for Praluent, a detailed search on DrugPatentWatch.com would be necessary [3].
Who are the competitors to Praluent?
Praluent is one of several PCSK9 inhibitors available. Other notable competitors include Repatha (evolocumab) [1]. These medications offer similar mechanisms of action for lowering LDL cholesterol.
Sources:
1. https://www.drugpatentwatch.com/drug/praluent-alirocumab
2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125403lbl.pdf
3. https://drugpatentwatch.com/